Abstract: The invention discloses a human adenovirus species C having a capsid which comprises a modified adenovirus hexon protein, wherein the modified adenovirus hexon protein has a modified HVR1 region, wherein the modified HVR1 region has the sequence DEAATALEINLKKKKQAEQQ (SEQ ID NO.: 1). The invention further discloses the adenovirus of the disclosure for use in treating or preventing a human disease. The invention further discloses a nucleic acid encoding the modified adenovirus hexon protein. The invention further discloses the use of an adenovirus according to the disclosure for transducing mesenchymal stromal cells (MSCs) or tumor cells. The invention further discloses an in vitro method for transducing MSCs and a transduced MSC obtainable by the method. The invention further discloses the transduced MSC of the disclosure for use in treating a disease.

Abstract: The invention generally concerns the production of defective Adenovirus helper viruses for producing a recombinant adeno-associated virus (rAAV), wherein the Adenovirus helper virus contains at least one mutation selected from (a) an inactivating mutation in the transcription unit coding for the L4-100K protein; (b) an inactivating mutation in the transcription unit coding for the L1-52/55K protein; (c) an inactivating mutation in the transcription unit coding for the preterminal protein (pTP); (d) a mutation in the L4-100K protein in order to render it temperature-sensitive (ts); (e) a mutation in the hexon protein in order to render it temperature-sensitive (ts); and/or (f) a mutation in the L4-00K protein and a mutation in the hexon protein in order to render it temperature-sensitive (ts).

Abstract: The present invention is related to a nucleic acid construct comprising an expression unit for the expression of E1B, wherein the expression unit comprises a promoter, a nucleotide sequence coding for E1B, and a 3?UTR, wherein the promoter is operatively linked to the nucleotide sequence coding for E1B, wherein the 3?UTR comprises 30 or less than 30 Exonic Enhancer Elements (ESEs), preferably 20 or less than 20 Exonic Enhancer Elements (ESEs), and wherein the 3? UTR is a non-viral 3? UTR.

Abstract: The present invention is related to a nucleic acid construct comprising an expression unit for the expression of E1B, wherein the expression unit comprises a promoter, a nucleotide sequence coding for E1B, and a 3?UTR, wherein the promoter is operatively linked to the nucleotide sequence coding for E1B, wherein the 3?UTR comprises 30 or less than 30 Exonic Enhancer Elements (ESEs), preferably 20 or less than 20 Exonic Enhancer Elements (ESEs), and wherein the 3? UTR is a non-viral 3? UTR.

Abstract: This invention relates to viral vector particles, including capsid proteins with an attachment site for the specific chemical modification of the vector particles. Furthermore, the invention relates to procedures for the production of these viral vector particles. Furthermore, the invention relates to the use of these viral vector particles as a therapeutic, prophylactic or diagnostic means in humans and primates as well as other vertebrates like cattle, pigs, birds, fish, or rodents.

Abstract: This invention relates to viral vector particles, including capsid proteins with an attachment site for the specific chemical modification of the vector particles. Furthermore, the invention relates to procedures for the production of these viral vector particles. Furthermore, the invention relates to the use of these viral vector particles as a therapeutic, prophylactic or diagnostic means in humans and primates as well as other vertebrates like cattle, pigs, birds, fish, or rodents.

Abstract: This invention relates to viral vector particles, including capsid proteins with an attachment site for the specific chemical modification of the vector particles. Furthermore, the invention relates to procedures for the production of these viral vector particles. Furthermore, the invention relates to the use of these viral vector particles as a therapeutic, prophylactic or diagnostic means in humans and primates as well as other vertebrates like cattle, pigs, birds, fish, or rodents.

Abstract: The present invention relates to a pigment epithelial cell of the eye containing vector DNA of an adenoviral vector with large DNA capacity, to the improved isolation and cultivation of these cells and to methods for production and the use in the therapy of an eye or nerve disease.

Abstract: The present invention relates to a pigment epithelial cell of the eye containing vector DNA of an adenoviral vector with large DNA capacity, to the improved isolation and cultivation of these cells and to methods for production and the use in the therapy of an eye or nerve disease.

Abstract: The invention relates to adenoviral vectors. More particularly, this invention relates to recombinant high capacity adenoviral vectors which can be employed in the treatment of hemophilia A, as well as methods and process for their creation and use.

Abstract: This invention relates to viral vector particles, including capsid proteins with an attachment site for the specific chemical modification of the vector particles. Furthermore, the invention relates to procedures for the production of these viral vector particles. Furthermore, the invention relates to the use of these viral vector particles as a therapeutic, prophylactic or diagnostic means in humans and primates as well as other vertebrates like cattle, pigs, birds, fish, or rodents.

Abstract: The present invention relates to adenoviral delivery of modified steroid hormone receptor proteins. The adenoviral vector preferably contains no viral coding sequence and is capable of accepting a large insert. Such vectors preferably are capable of achieving high levels and durations of delivery and expression. The modified protein preferably is capable of distinguishing a hormone agonist from an antagonist and may be modified in the ligand binding domain, the DNA binding domain, and/or the transregulatory domain.

Abstract: The invention relates to adenoviral vectors. More particularly, this invention relates to recombinant high capacity adenoviral vectors which can be employed in the treatment of hemophilia A, as well as methods and process for their creation and use.

Abstract: The present invention relates to a pigment epithelial cell of the eye containing vector DNA of an adenoviral vector with large DNA capacity, to the improved isolation and cultivation of these cells and to methods for production and the use in the therapy of an eye or nerve disease.

Abstract: The invention relates to a permanent amniocytic cell line comprising at least one nucleic acid which brings about expression of the gene products of the adenovirus E1A and E1B regions. The present invention further relates to the production of a permanent amniocytic cell line and to its use for producing gene transfer vectors and/or adenovirus mutants. Further aspects are the use of amniocytes and of the adenoviral gene products of the E1A and E1B regions for producing permanent amniocytic cell lines.

Abstract: A gene transfer vector comprising adenovirus inverted terminal repeats, recombinant adenovirus particles containing the same, a method for producing the same and a method of use of the same to introduce and express a foreign gene in eukaryotic cells, and to treat muscular dystrophy, is disclosed.

Abstract: A gene transfer vector comprising adenovirus inverted terminal repeats, at least one adenovirus packaging signal, and an adenoviral VAI gene and/or VAII gene; recombinant adenovirus particles containing the same; a method for producing the same and a method of use of the same to introduce and express a foreign gene in adenovirus target cells, is disclosed.